Ocera Therapeutics's basic earnings per share (Basic EPS) for the
three
months ended in Sep. 2017 was $-0.24.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.96.
Ocera Therapeutics's EPS without NRI for the
three
months ended in Sep. 2017 was $-0.24.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2017 was -0.96.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
Ocera Therapeutics EPS (Basic) Historical Data
The historical data trend for Ocera Therapeutics's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Ocera Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2016 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.96
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Ocera Therapeutics EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Ocera Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocera Therapeutics (Ocera Therapeutics) Business Description
Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company, which primarily targets acute and chronic orphan liver diseases. The company is focused on the development and commercialization of a clinical product candidate, OCR-002 for the treatment of acute and chronic hepatic encephalopathy for patients with a serious complication of liver cirrhosis, or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and, in its more severe form, stupor, coma and even death. All the business activity of the firm is functioned through the region of US.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCRX has been successfully added to your 